We are live on ! Find out more

2,525 hedge funds and large institutions have $157B invested in Pfizer in 2019 Q4 according to their latest regulatory filings, with 311 funds opening new positions, 1,008 increasing their positions, 970 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

304% more first-time investments, than exits

New positions opened: 311 | Existing positions closed: 77

32% more funds holding in top 10

Funds holding in top 10: 81107 (+26)

10% more capital invested

Capital invested by funds: $142B → $157B (+$14.4B)

9% more funds holding

Funds holding: 2,3232,525 (+202)

4% more repeat investments, than reductions

Existing positions increased: 1,008 | Existing positions reduced: 970

0.55% more ownership

Funds ownership: 75.55%76.09% (+0.55%)

16% less call options, than puts

Call options by funds: $1.19B | Put options by funds: $1.41B

Holders
2,525
Holders Change
+202
Holders Change %
+8.7%
% of All Funds
49.74%
Holding in Top 10
107
Holding in Top 10 Change
+26
Holding in Top 10 Change %
+32.1%
% of All Funds
2.11%
New
311
Increased
1,008
Reduced
970
Closed
77
Calls
$1.19B
Puts
$1.41B
Net Calls
-$224M
Net Calls Change
+$45.8M
Name Holding Trade Value Shares
Change
Change in
Stake
FIM
1376
Freedom Investment Management
Connecticut
$1.51M -$413K -11,589 -22%
UCMOK
1377
United Capital Management of KS
Kansas
$1.51M +$158K +4,442 +12%
MBI
1378
Montrusco Bolton Investments
Quebec, Canada
$1.51M -$177K -4,969 -11%
CFA
1379
CWS Financial Advisors
Michigan
$1.51M +$1.44M +40,513 New
VDFA
1380
Vickerman & Driscoll Financial Advisors
Washington
$1.5M -$3.03K -85 -0.2%
TCM
1381
Traynor Capital Management
Pennsylvania
$1.5M +$145K +4,082 +11%
CGL
1382
Clarius Group LLC
Washington
$1.5M +$7.91K +222 +0.6%
DAM
1383
Delta Asset Management
Tennessee
$1.5M +$11.1K +313 +0.8%
TCM
1384
Telos Capital Management
California
$1.5M +$364K +10,217 +34%
CCA
1385
Cobblestone Capital Advisors
New York
$1.5M -$112K -3,150 -7%
CNFG
1386
Creegan & Nassoura Financial Group
New Hampshire
$1.49M +$1.43M +40,174 New
AWM
1387
Aries Wealth Management
Maine
$1.49M
RFA
1388
Reilly Financial Advisors
California
$1.49M +$42K +1,180 +3%
IWA
1389
IBEX Wealth Advisors
New Jersey
$1.48M +$12.8K +358 +0.9%
BJL
1390
Brighton Jones LLC
Washington
$1.48M +$37.1K +1,042 +3%
KC
1391
Kingfisher Capital
North Carolina
$1.48M -$16.8K -471 -1%
CIG
1392
Cairn Investment Group
Washington
$1.48M +$1.41M +39,724 New
MCWS
1393
McKinley Carter Wealth Services
West Virginia
$1.47M +$42.8K +1,202 +3%
FNFDCM
1394
Folger Nolan Fleming Douglas Capital Management
District of Columbia
$1.47M
SCM
1395
Southport Capital Management
Tennessee
$1.47M -$117K -3,277 -8%
NB
1396
Nicolet Bankshares
Wisconsin
$1.46M -$2.74K -77 -0.2%
EH
1397
Equitable Holdings
New York
$1.46M +$1.4M +39,366 New
FFG
1398
Frisch Financial Group
New York
$1.45M +$253K +7,113 +22%
BDF
1399
Balasa Dinverno & Foltz
$1.45M -$504K -14,149 -27%
SIAP
1400
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$1.44M +$109K +3,048 +9%

PFE Hedge Fund Activity: Q4 2019 in Review

2,525 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2019, worth a combined $157B — up 10% from $142B a quarter earlier.

Buyers outnumbered sellers: 311 funds opened new PFE positions and 77 closed out — a net gain of 234 holders — while 1,008 added to existing stakes and 970 trimmed.

The largest buyer was Capital World Investors, adding an estimated $835M. The largest seller was JP Morgan Chase, cutting an estimated $1.43B.

  • 2,525 institutional investors held Pfizer (PFE) as of Q4 2019, up from 2,323 in Q3 2019.
  • Funds reported $157B of Pfizer stock for Q4 2019, up 10% quarter-over-quarter.
  • 311 funds opened new Pfizer positions in Q4 2019 and 77 closed out, a net change of +234 holders.
  • The largest Pfizer buyer in Q4 2019 was Capital World Investors, an estimated $835M added.
  • The largest Pfizer seller in Q4 2019 was JP Morgan Chase, an estimated $1.43B sold.

Based on aggregated 13F filings for Q4 2019.